Melissa Cunningham

Melissa Cunningham

Auto-generated profile, based on publicly available information

Melissa Cunningham

Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Cancer Research Communications
Verified
Journal Article
Open access
KPKatherine R. Pelz
Katherine R. Pelz
PJPhilip Jimenez
Philip Jimenez
CDColin J. Daniel
Colin J. Daniel
SNSamuel D. Newton
Samuel D. Newton
MCMelissa Cunningham
Melissa Cunningham
TZTeresa A. Zimmers
Teresa A. Zimmers
Preclinical models of pancreatic ductal adenocarcinoma (PDAC) can greatly benefit from noninvasive imaging for evaluating disease progression and therapeutic response. Imaging approaches that can accurately and simultaneously track primary tumor growth, metastatic dissemination, and host cachexia over time are lacking. Herein, we report an optimized dual-contrast microCT protocol for longitudinal imaging in orthotopic murine models of PDAC. This method enables high-resolution, volumetric quantification of orthotopic primary tumors, liver and lung metastases, and paraspinal skeletal muscle, providing a dynamic view of both the tumor and host physiology. MicroCT primary tumor measurements were strongly correlated with endpoint tumor weights and outperformed 2D ultrasound in early detection and volumetric accuracy, particularly for small or irregularly shaped tumors. This platform revealed heterogeneous metastatic kinetics across PDAC models and uncovered an early, heterogeneous onset of skeletal muscle wasting, a hallmark of cancer cachexia. Notably, this protocol mimics clinical CT surveillance by enabling opportunistic cachexia assessment from tumor imaging datasets and offers substantial advantages over destructive endpoint analyses. Furthermore, microCT radiation dose had no effect on model endpoints. By capturing the temporal dynamics of tumor progression and host response, dual-contrast microCT serves as a powerful translational platform for preclinical PDAC research and therapeutic testing. Significance: Dual-contrast microCT provides high-resolution, whole-body, noninvasive imaging in orthotopic murine PDAC models, enabling simultaneous tracking of tumor growth, metastasis, and skeletal muscle wasting, offering a clinically relevant, translational imaging platform.

22 December 2025
Verified
Other
Open access
KPKatherine R. Pelz
Katherine R. Pelz
PJPhilip Jimenez
Philip Jimenez
CDColin J. Daniel
Colin J. Daniel
SNSamuel D. Newton
Samuel D. Newton
MCMelissa Cunningham
Melissa Cunningham
TZTeresa A. Zimmers
Teresa A. Zimmers
Biodistribution of iohexol contrast injected intraperitoneally

22 December 2025
Verified
Other
Open access
KPKatherine R. Pelz
Katherine R. Pelz
PJPhilip Jimenez
Philip Jimenez
CDColin J. Daniel
Colin J. Daniel
SNSamuel D. Newton
Samuel D. Newton
MCMelissa Cunningham
Melissa Cunningham
TZTeresa A. Zimmers
Teresa A. Zimmers
Longitudinal monitoring of PDAC tumor kinetics using microCT imaging and volumetric comparisons with 2D US. A, Representative axial microCT image showing the primary tumor (red outline). B, 3D reconstruction showing the primary tumor (red) and skeleton of the mouse rendered in grayscale. C, Correlation of primary tumor volume measured by microCT with tumor weight at endpoint (N = 27, Pearson’s r = 0.9734; P < 0.0001; R2 = 0.9475). D, Schematic and representative US images showing how primary tumor volume was estimated by 2D US. Axial and sagittal slices at the largest tumor dimensions were obtained, and area (A) and height (H) measurements were used to derive cylindrical volumes for each plane. Tumor volumes were calculated by averaging the volumes of the axial and sagittal cylinders and applying a spherical volume correction factor (2/3). E, Correlation between US- and microCT-derived primary tumor volumes (R2 = 0.6349, P = 0.0011). F, Correlation between US- and microCT-derived primary tumor volumes for subset of tumors smaller than 700 mm3 (as determined by microCT; R2 = 0.00, P = 0.9839).

22 December 2025
Verified
Other
Open access
KPKatherine R. Pelz
Katherine R. Pelz
PJPhilip Jimenez
Philip Jimenez
CDColin J. Daniel
Colin J. Daniel
SNSamuel D. Newton
Samuel D. Newton
MCMelissa Cunningham
Melissa Cunningham
TZTeresa A. Zimmers
Teresa A. Zimmers
Study experimental timeline. Mice were orthotopically implanted with PDAC cells or PBS (day 0), injected with VivoVist (24 hours before the first scan) and iohexol (before each scan), and scanned every 3 to 4 days starting on day 8. Mice were euthanized upon reaching humane criteria (Hickman score ≤3; ref. 9).

22 December 2025
Verified
Other
Open access
KPKatherine R. Pelz
Katherine R. Pelz
PJPhilip Jimenez
Philip Jimenez
CDColin J. Daniel
Colin J. Daniel
SNSamuel D. Newton
Samuel D. Newton
MCMelissa Cunningham
Melissa Cunningham
TZTeresa A. Zimmers
Teresa A. Zimmers
Tumor-induced wasting of heart tissue

22 December 2025
Verified
Other
Open access
KPKatherine R. Pelz
Katherine R. Pelz
PJPhilip Jimenez
Philip Jimenez
CDColin J. Daniel
Colin J. Daniel
SNSamuel D. Newton
Samuel D. Newton
MCMelissa Cunningham
Melissa Cunningham
TZTeresa A. Zimmers
Teresa A. Zimmers
Supplementary Figure 1 from MicroCT Enables Simultaneous Longitudinal Tracking of Murine Pancreatic Cancer Progression and Cachexia